Form 8-K Performant Financial For: Aug 08
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 8, 2022
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (925) 960-4800
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||||||
The | ||||||||
| Item 2.02 | Results of Operations and Financial Condition. | ||||
On August 8, 2022 Performant Financial Corporation issued a press release announcing financial results for its quarter ended June 30, 2022. The full text of the press release is furnished as Exhibit 99.1.
The information furnished in this Form 8-K, including the exhibit attached, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. | ||||
(d)Exhibits
| 99.1 | |||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 8, 2022
| PERFORMANT FINANCIAL CORPORATION | ||||||||
| By: | /s/ Ian Johnston | |||||||
| Ian Johnston | ||||||||
| Chief Accounting Officer | ||||||||
Exhibit 99.1
Performant Financial Corporation Announces Financial Results for Second Quarter 2022
Livermore, Calif., August 8, 2022 - Performant Financial Corporation (Nasdaq: PFMT), (the "Company"), a leading provider of technology-enabled audit, recovery, and related analytics services in the United States with a focus in the healthcare payment integrity services industry, today reported the following financial results for its second quarter ended June 30, 2022:
Second Quarter Financial Highlights
•Total revenues of $25.7 million, compared to revenues of $32.8 million in the prior year period.
•Healthcare revenues of $21.8 million, compared to $18.6 million in the prior year period, an increase of 17.0%
•Net loss of approximately $(3.2) million, or $(0.04) per diluted share, compared to net loss of $(1.5) million, or $(0.03) per diluted share, in the prior year period.
•Adjusted net loss was $(2.9) million, or $(0.04) per diluted share, compared to adjusted net income of 0.5 million, or $0.01 per diluted share, in the prior year period.
•Adjusted EBITDA of $(1.4) million, compared to $4.2 million in the prior year period.
Second Quarter 2022 Results
Total revenues in the second quarter were $25.7 million, a decrease from revenues of $32.8 million in the prior year period. Healthcare revenues in the second quarter of 2022 were $21.8 million, an increase of 17% from revenues of $18.6 million in the prior year period. Within Healthcare, claims-based services revenue in the second quarter of 2022 was $9.3 million, while revenues from eligibility-based services in the second quarter was $12.4 million.
“The second quarter of 2022, marked yet another quarter of strong year-over-year growth in our healthcare revenues supported by our robust sales pipeline and steady implementation conversion,” stated Simeon Kohl, President of Performant. “We are also pleased to announce that Melissa Christ has joined Performant as Chief People Officer. Melissa brings over 20 years of experience in people strategy and working with high-growth companies. People are at the core of everything we do, and we are excited to have such an experienced leader to help navigate this important period of growth.”
Recovery revenues in the second quarter were $7 thousand, a decrease of 99.9% from revenues of $11.1 million in the prior year period due to the cessation of non-healthcare recovery activity which largely occurred by the end of 2021. Revenues from our Customer Care / Outsourced Services in the second quarter were $3.9 million, up $0.8 million compared to the prior year period.
Net loss for the second quarter was $3.2 million, or $(0.04) per share on a diluted basis, compared to a net loss of $1.5 million, or $(0.03) per share on a diluted basis, in the prior year period. Adjusted net loss for the second quarter was $2.9 million, or $(0.04) per share on a diluted basis, compared to adjusted net income of $0.5 million, or $0.01 per diluted share, in the prior year period. Adjusted EBITDA for the second quarter was $(1.4) million as compared to $4.2 million in the prior year period.
As of June 30, 2022, the Company had cash, cash equivalents, and restricted cash of approximately $18.2 million.
“Given our continued achievements in the second quarter, and in combination with the KPI and opportunity growth ahead of us, we remain pleased with how we are tracking toward current year expectations and more importantly, our long term goals,” stated Rohit Ramchandani, Senior Vice President of Finance and Strategy at Performant. “Despite a tumultuous macroeconomic climate we remain well capitalized and positioned to continue executing against our investment strategies, which will promote continued long-term growth. As we look ahead to the second half of the year, we are pleased to reiterate our Healthcare revenue and adjusted EBITDA guidance ranges for 2022 of $92-$96MM and $2-$4 million respectively.”
Note Regarding Use of Non-GAAP Financial Measures
In this press release, to supplement our consolidated financial statements, the Company presents adjusted EBITDA, adjusted net income (loss), and adjusted net income (loss) per diluted share. These measures are not in accordance with accounting principles generally accepted in the United States of America (US GAAP) and accordingly reconciliations of adjusted EBITDA and adjusted net income (loss) to net income (loss) determined in accordance with US GAAP are included in the “Reconciliation of Non-GAAP Results” table at the end of this press release. We have included adjusted EBITDA and adjusted net income (loss) in this press release because they are key measures used by our management and board of directors to understand and evaluate our core operating performance and trends and to prepare and approve our annual budget. Accordingly, we believe that adjusted EBITDA and adjusted net income (loss) provide useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and board of directors. Our use of adjusted EBITDA and adjusted net income (loss) has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under US GAAP. In particular, many of the adjustments to our US GAAP financial measures reflect the exclusion of items, specifically interest, tax and depreciation and amortization expenses, equity-based compensation expense and certain other non-operating expenses, that are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be calculated differently from similarly titled non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.
Earnings Conference Call
The Company will hold a conference call to discuss its second quarter 2022 results today at 5:00 p.m. Eastern. A live webcast of the call may be accessed on the Investor Relations section of the Company’s website at investors.performantcorp.com. The conference call is also available by dialing 877-704-4453 (domestic) or 201-389-0920 (international).
A replay of the call will be available on the Company's website or by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and entering the passcode 13731883. The telephonic replay will be available approximately three hours after the call, through August 15, 2022.
About Performant Financial Corporation
Performant is a leading provider of technology-enabled audit, recovery, and analytics services in the United States with a focus in the healthcare payment integrity industry. Performant works with healthcare payers through claims auditing and eligibility-based (also known as coordination-of-benefits) services to identify improper payments. The Company engages clients in both government and commercial markets. The Company also has a call center which serves clients with complex consumer engagement needs. Clients of the Company typically operate in complex and highly regulated environments and contract for their payment integrity needs in order to reduce losses on improper healthcare payments.
Powered by a proprietary analytic platform and workflow technology, Performant also provides professional services related to the recovery effort, including reporting capabilities, support services, customer care and stakeholder training programs meant to mitigate future instances of improper payments. Founded in 1976, Performant is headquartered in Livermore, California.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's outlook for revenues, net income (loss), and adjusted EBITDA in 2022 and beyond. These forward-looking statements are based on current expectations, estimates, assumptions and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, that the Company faces a long period to implement a new contract which may result in the incurring of expenses before the receipt of revenues from new client relationships, that the high level of revenue concentration among the Company's largest customers and any termination of or deterioration in the Company’s relationship with any of its significant clients would result in a material decline in revenues, that many of the Company's customer contracts are subject to periodic renewal, are not exclusive, do not provide for committed business volumes and may be changed or terminated unilaterally and on short notice, that the U.S. federal government accounts for a significant portion of the Company's revenues, that downturns in domestic or global economic conditions and other macroeconomic factors could harm the Company’s business and results of operations, that the Company may not have sufficient cash flows from operations to fund ongoing operations and other liquidity needs, that the Company may not be able to manage its potential growth effectively, that the Company faces significant competition in all of its markets, the material adverse impact of the COVID-19 pandemic on the Company's business, results of operations and financial condition as well as on the business operations and financial performance of many of its customers, that limitations on the scope of the Company's audit activity under its claims audit contracts may reduce revenue opportunities, that the Company’s indebtedness could adversely affect its business and financial condition and could reduce the funds available for other purposes and the failure to comply with covenants contained in its credit agreement could result in an event of default that could adversely affect its results of operations, that future legislative and regulatory changes may have significant effects on the Company's business, that failure of the Company's or third parties' operating systems and technology infrastructure could disrupt the operation of the Company's business and the threat of breach of the Company's security measures or failure or unauthorized access to confidential data that the Company possesses. More information on potential factors that could affect the Company's financial condition and operating results is included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's annual report on Form 10-K for the year ended December 31, 2021 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this press release and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.
Contact Information
Richard Zubek
Investor Relations
925-960-4988
investors@performantcorp.com
PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Consolidated Balance Sheets
(In thousands, except per share amounts)
| June 30, 2022 | December 31, 2021 | ||||||||||
| (Unaudited) | |||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 15,973 | $ | 17,347 | |||||||
| Restricted cash | 2,203 | 2,203 | |||||||||
Trade accounts receivable, net of allowance for doubtful accounts of $29 and $—, respectively | 19,880 | 20,808 | |||||||||
| Contract assets | 9,197 | 8,113 | |||||||||
| Prepaid expenses and other current assets | 3,334 | 3,077 | |||||||||
| Income tax receivable | 3,248 | 3,159 | |||||||||
| Total current assets | 53,835 | 54,707 | |||||||||
| Property, equipment, and leasehold improvements, net | 15,036 | 15,708 | |||||||||
| Goodwill | 47,372 | 47,372 | |||||||||
| Right-of-use assets | 2,647 | 3,235 | |||||||||
| Other assets | 969 | 963 | |||||||||
| Total assets | $ | 119,859 | $ | 121,985 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
Current maturities of notes payable, net of unamortized debt issuance costs of $14 and $11, respectively | $ | 736 | $ | 489 | |||||||
| Accrued salaries and benefits | 7,395 | 8,476 | |||||||||
| Accounts payable | 963 | 1,124 | |||||||||
| Other current liabilities | 2,124 | 3,732 | |||||||||
| Contract liabilities | 366 | 634 | |||||||||
| Estimated liability for appeals and disputes | 1,076 | 1,190 | |||||||||
| Lease liabilities | 1,404 | 1,862 | |||||||||
| Total current liabilities | 14,064 | 17,507 | |||||||||
Notes payable, net of current portion and unamortized debt issuance costs of $366 and $416, respectively | 18,634 | 19,084 | |||||||||
| Lease liabilities | 1,557 | 1,803 | |||||||||
| Other liabilities | 1,179 | 1,168 | |||||||||
| Total liabilities | 35,434 | 39,562 | |||||||||
Commitments and contingencies (note 3 and note 4) | |||||||||||
| Stockholders’ equity: | |||||||||||
Common stock, $0.0001 par value. Authorized, 500,000 shares at June 30, 2022 and December 31, 2021 respectively; issued and outstanding 73,818 and 69,281 shares at June 30, 2022 and December 31, 2021, respectively | 7 | 7 | |||||||||
| Additional paid-in capital | 140,506 | 133,662 | |||||||||
| Accumulated deficit | (56,088) | (51,246) | |||||||||
| Total stockholders’ equity | 84,425 | 82,423 | |||||||||
| Total liabilities and stockholders’ equity | $ | 119,859 | $ | 121,985 | |||||||
PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||
| Revenues | $ | 25,681 | $ | 32,842 | $ | 52,764 | $ | 64,232 | ||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Salaries and benefits | 20,903 | 23,295 | 41,342 | 47,385 | ||||||||||||||||||||||
| Other operating expenses | 8,081 | 10,759 | 16,212 | 21,115 | ||||||||||||||||||||||
| Total operating expenses | 28,984 | 34,054 | 57,554 | 68,500 | ||||||||||||||||||||||
| Loss from operations | (3,303) | (1,212) | (4,790) | (4,268) | ||||||||||||||||||||||
| Interest expense | (216) | (2,126) | (371) | (3,472) | ||||||||||||||||||||||
| Loss before provision for income taxes | (3,137) | (1,489) | (4,779) | (5,891) | ||||||||||||||||||||||
| Provision for income taxes | 32 | 33 | 63 | 70 | ||||||||||||||||||||||
| Net loss | $ | (3,169) | $ | (1,522) | $ | (4,842) | $ | (5,961) | ||||||||||||||||||
| Net loss per share | ||||||||||||||||||||||||||
| Basic | $ | (0.04) | $ | (0.03) | $ | (0.07) | $ | (0.11) | ||||||||||||||||||
| Diluted | $ | (0.04) | $ | (0.03) | $ | (0.07) | $ | (0.11) | ||||||||||||||||||
| Weighted average shares | ||||||||||||||||||||||||||
| Basic | 73,502 | 55,516 | 71,698 | 55,167 | ||||||||||||||||||||||
| Diluted | 73,502 | 55,516 | 71,698 | 55,167 | ||||||||||||||||||||||
PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
| Six Months Ended June 30, | |||||||||||
| 2022 | 2021 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net loss | $ | (4,842) | $ | (5,961) | |||||||
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||||||||||
| Loss (gain) on disposal of assets and impairment of long-lived assets | (15) | 674 | |||||||||
| Depreciation and amortization | 2,260 | 3,040 | |||||||||
| Right-of-use assets amortization | 588 | 1,015 | |||||||||
| Stock-based compensation | 1,281 | 1,423 | |||||||||
| Interest expense from debt issuance costs | 48 | 1,133 | |||||||||
| Gain on sale of certain recovery contracts | (382) | (1,849) | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Trade accounts receivable | 928 | 3,417 | |||||||||
| Contract assets | (1,084) | (1,304) | |||||||||
| Prepaid expenses and other current assets | (257) | 564 | |||||||||
| Income tax receivable | (89) | (934) | |||||||||
| Other assets | (6) | 121 | |||||||||
| Accrued salaries and benefits | (1,081) | (1,072) | |||||||||
| Accounts payable | (161) | 439 | |||||||||
| Contract liabilities and other current liabilities | (1,860) | (1,147) | |||||||||
| Estimated liability for appeals and disputes | (114) | 3,486 | |||||||||
| Lease liabilities | (704) | (1,167) | |||||||||
| Other liabilities | 12 | (414) | |||||||||
| Net cash (used in) provided by operating activities | (5,478) | 1,464 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchase of property, equipment, and leasehold improvements | (1,589) | (1,604) | |||||||||
| Proceeds from sale of certain recovery contracts | 382 | 2,406 | |||||||||
| Net cash (used in) provided by investing activities | (1,207) | 802 | |||||||||
| Cash flows from financing activities: | |||||||||||
| Repayment of notes payable | (250) | (7,650) | |||||||||
| Debt issuance costs paid | (2) | (150) | |||||||||
| Taxes paid related to net share settlement of stock awards | — | (633) | |||||||||
| Proceeds from exercise of warrants | 5,563 | 23 | |||||||||
| Net cash provided by (used in) financing activities | 5,311 | (8,410) | |||||||||
| Net decrease in cash, cash equivalents and restricted cash | (1,374) | (6,144) | |||||||||
| Cash, cash equivalents and restricted cash at beginning of period | 19,550 | 18,296 | |||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 18,176 | $ | 12,152 | |||||||
| Reconciliation of the Consolidated Statements of Cash Flows to the Consolidated Balance Sheets: | |||||||||||
| Cash and cash equivalents | $ | 15,973 | $ | 9,949 | |||||||
| Restricted cash | 2,203 | 2,203 | |||||||||
| Total cash, cash equivalents and restricted cash at end of period | $ | 18,176 | $ | 12,152 | |||||||
| Non-cash financing activities: | |||||||||||
| Recognition of earnout shares issued | $ | — | $ | 801 | |||||||
| Recognition of warrants associated with notes payable | $ | — | $ | 5,237 | |||||||
| Supplemental disclosures of cash flow information: | |||||||||||
| Cash paid for income taxes | $ | 238 | $ | 1,482 | |||||||
| Cash paid for interest | $ | 244 | $ | 2,340 | |||||||
PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Reconciliation of Non-GAAP Results
(In thousands, except per share amount)
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||||||||||||
| Adjusted EBITDA: | ||||||||||||||||||||||||||
| Net income (loss) | $ | (3,169) | $ | (1,522) | $ | (4,842) | $ | (5,961) | ||||||||||||||||||
| Provision for income taxes | 32 | 33 | 63 | 70 | ||||||||||||||||||||||
Interest expense (1) | 216 | 2,126 | 371 | 3,472 | ||||||||||||||||||||||
| Stock-based compensation | 723 | 774 | 1,281 | 1,423 | ||||||||||||||||||||||
| Depreciation and amortization | 1,158 | 2,024 | 2,260 | 3,040 | ||||||||||||||||||||||
| Impairment of long-lived assets | — | — | — | 636 | ||||||||||||||||||||||
Severance expenses (4) | 37 | 1,188 | 179 | 1,496 | ||||||||||||||||||||||
Non-core operating expenses (5) | 2 | $ | 1,397 | 6 | 1,908 | |||||||||||||||||||||
Gain on sale of certain recovery contracts (6) | (382) | (1,849) | (382) | (1,849) | ||||||||||||||||||||||
| Adjusted EBITDA | $ | (1,383) | $ | 4,171 | $ | (1,064) | $ | 4,235 | ||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||||||||||||
| Adjusted Net Income (Loss): | ||||||||||||||||||||||||||
| Net income (loss) | $ | (3,169) | $ | (1,522) | $ | (4,842) | $ | (5,961) | ||||||||||||||||||
| Stock-based compensation | 723 | 774 | 1,281 | 1,423 | ||||||||||||||||||||||
Amortization of intangible assets (2) | — | 558 | — | 617 | ||||||||||||||||||||||
Amortization of debt issuance costs (3) | 24 | 764 | 48 | 1,133 | ||||||||||||||||||||||
| Impairment of long-lived assets | — | — | — | 636 | ||||||||||||||||||||||
Severance expenses (4) | 37 | 1,188 | 179 | 1,496 | ||||||||||||||||||||||
Non-core operating expenses (5) | 2 | 1,397 | 6 | 1,908 | ||||||||||||||||||||||
Gain on sale of certain recovery contracts (6) | (382) | (1,849) | (382) | (1,849) | ||||||||||||||||||||||
Tax adjustments (7) | (111) | (779) | (311) | (1,475) | ||||||||||||||||||||||
| Adjusted net income (loss) | $ | (2,876) | $ | 531 | $ | (4,021) | $ | (2,072) | ||||||||||||||||||
PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Reconciliation of Non-GAAP Results
(In thousands, except per share amount)
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||||||||||||
| Adjusted Net Income (Loss) Per Diluted Share: | ||||||||||||||||||||||||||
| Net income (loss) | $ | (3,169) | $ | (1,522) | $ | (4,842) | $ | (5,961) | ||||||||||||||||||
| Plus: Adjustment items per reconciliation of adjusted net income (loss) | 293 | 2,053 | 821 | 3,889 | ||||||||||||||||||||||
| Adjusted net income (loss) | $ | (2,876) | $ | 531 | $ | (4,021) | $ | (2,072) | ||||||||||||||||||
| Adjusted net income (loss) per diluted share | $ | (0.04) | $ | 0.01 | $ | (0.06) | $ | (0.04) | ||||||||||||||||||
Diluted average shares outstanding (8) | 73,502 | 60,617 | 71,698 | 55,167 | ||||||||||||||||||||||
We are providing the following preliminary estimates of our financial results as follows:
| Six Months Ended | Six Months Ended | Year Ended | ||||||||||||||||||||||||
| June 30, 2022 | December 31, 2022 | December 31, 2021 | December 31, 2022 | |||||||||||||||||||||||
| Actual | Estimate | Actual | Estimate | |||||||||||||||||||||||
| Adjusted EBITDA: | ||||||||||||||||||||||||||
| Net income (loss) | $ | (4,842) | $ (282) to (2,287) | $ | (10,288) | $ (5,124) to (7,124) | ||||||||||||||||||||
| Provision for income taxes | 63 | (413) to 687 | 62 | (350) to 750 | ||||||||||||||||||||||
Interest expense (1) | 371 | 629 to 1,129 | 11,313 | 1,000 to 1,500 | ||||||||||||||||||||||
| Stock-based compensation | 1,281 | 719 to 1,719 | 2,640 | 2,000 to 3,000 | ||||||||||||||||||||||
| Depreciation and amortization | 2,260 | 2,490 to 3,490 | 5,188 | 4,750 to 5,750 | ||||||||||||||||||||||
| Impairment of long-lived assets | — | — | 636 | — | ||||||||||||||||||||||
Severance expenses (4) | 179 | (79) to 321 | 2,160 | 100 to 500 | ||||||||||||||||||||||
Non-core operating expenses (5) | 6 | — | 2,588 | 6 | ||||||||||||||||||||||
Gain on sale of certain recovery contracts (6) | (382) | — | (2,403) | (382) | ||||||||||||||||||||||
| Adjusted EBITDA | $ | (1,064) | $ | (1,064) | $ 3,064 to 5,064 | $ | 11,896 | $ 2,000 to 4,000 | ||||||||||||||||||
(1)Represents interest expense and amortization of debt issuance costs related to our Credit Agreement and Prior Credit Agreement.
(2)Represents amortization of intangibles related to the acquisition of Performant by an affiliate of Parthenon Capital Partners in 2004.
(3)Represents amortization of debt issuance costs related to our Credit Agreement and Prior Credit Agreement.
(4)Represents severance expenses incurred in connection with a reduction in force for our non-healthcare recovery services.
(5)Represents professional fees related to strategic corporate development activities.
(6)Represents gain on the sale of certain non-healthcare recovery contracts.
(7)Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.
(8)While net loss for the three months ended June 30, 2021 is ($1,522), the computation of adjusted net income results in adjusted net income of $531. Therefore, the calculation of the adjusted earnings per diluted share for the three months ended June 30, 2021 includes dilutive common share equivalents of 5,101 added to the basic weighted average shares of 55,516.
PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Reconciliation of Non-GAAP Results
(In thousands, except per share amount)
(Unaudited)
We are providing the following historical breakdown of the quarterly and annual revenue contributions under the new contribution breakdowns of our healthcare revenue results for the three and six months ended June 30, 2022, and for the years ended December 31, 2021 and 2020:
| For the Three Months Ended | For the Six Months Ended | |||||||||||||||||||
| March 31, 2022 | June 30, 2022 | June 30, 2022 | ||||||||||||||||||
| (in thousands) | ||||||||||||||||||||
| Eligibility-based | $ | 14,215 | $ | 12,417 | $ | 26,632 | ||||||||||||||
| Claims-based | 9,149 | 9,339 | 18,488 | |||||||||||||||||
| Healthcare Total | 23,364 | 21,756 | 45,120 | |||||||||||||||||
| Recovery | 118 | 7 | 125 | |||||||||||||||||
| Customer Care / Outsourced Services | 3,601 | 3,918 | 7,519 | |||||||||||||||||
| Total | $ | 27,083 | 25,681 | $ | 52,764 | |||||||||||||||
| For the Three Months Ended | For the Year Ended | |||||||||||||||||||||||||||||||
| March 31, 2021 | June 30, 2021 | September 30, 2021 | December 31, 2021 | December 31, 2021 | ||||||||||||||||||||||||||||
| Eligibility-based | $ | 7,911 | $ | 11,577 | $ | 12,727 | $ | 16,061 | $ | 48,276 | ||||||||||||||||||||||
| Claims-based | 5,375 | 7,025 | 7,280 | 9,498 | 29,178 | |||||||||||||||||||||||||||
| Healthcare Total | 13,286 | 18,602 | 20,007 | 25,559 | 77,454 | |||||||||||||||||||||||||||
| Recovery | 14,491 | 11,091 | 5,490 | 2,333 | 33,405 | |||||||||||||||||||||||||||
| Customer Care / Outsourced Services | 3,613 | 3,149 | 3,085 | 3,687 | 13,534 | |||||||||||||||||||||||||||
| Total | $ | 31,390 | $ | 32,842 | $ | 28,582 | $ | 31,579 | $ | 124,393 | ||||||||||||||||||||||
| For the Three Months Ended | For the Year Ended | |||||||||||||||||||||||||||||||
| March 31, 2020 | June 30, 2020 | September 30, 2020 | December 31, 2020 | December 31, 2020 | ||||||||||||||||||||||||||||
| Eligibility-based | $ | 10,949 | $ | 11,292 | $ | 13,480 | 14,126 | $ | 49,847 | |||||||||||||||||||||||
| Claims-based | 6,575 | 3,301 | 4,086 | 4,739 | 18,701 | |||||||||||||||||||||||||||
| Healthcare Total | 17,524 | 14,593 | 17,566 | 18,865 | 68,548 | |||||||||||||||||||||||||||
| Recovery | 24,265 | 16,167 | 15,443 | 17,521 | 73,396 | |||||||||||||||||||||||||||
| Customer Care / Outsourced Services | 4,099 | 3,025 | 3,219 | 3,650 | 13,993 | |||||||||||||||||||||||||||
| Total | $ | 45,888 | $ | 33,785 | $ | 36,228 | $ | 40,036 | $ | 155,937 | ||||||||||||||||||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Performant Financial Corporation to Report First Quarter 2024 Earnings on May 7, 2024
- Perk Labs Announces Closing of Non-Brokered Private Placements
- Banco Itaú Chile Files Material Event Notice announcing Extraordinary General Shareholders’ Meeting Agreements
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
